Login / Register Order My Items
mob-logo
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

Nuclease-Resistant & Stabilized Oligonucleotide Design

Application-focused stabilization strategies for ASO, siRNA, gapmer, aptamer, PMO, PNA, diagnostic probe and research oligonucleotide designs.

45+ Years of Expertise ISO 9001:2015 / ISO13485:2016 Bench to Kilo Scale Confidential & IP-Protected U.S.A Facilities - Texas
Start by Application View Chemistry Tables
Talk to a chemist Request a quote
Overview Decision Guide Chemistry Toolkit Selection Table Quick Recipes Applications FAQ Reading Contact
Overview

Build Stability Around the Biology

Nuclease-resistant oligonucleotides are DNA, RNA or synthetic nucleic acid constructs engineered to survive serum, cells, lysates, tissue homogenates or in vivo research environments. Instead of choosing a chemistry name first, the best design starts with the biological goal: RNase H knockdown, RNAi, aptamer binding, splice blocking, diagnostic probing or maximum scaffold stability.

Bio-Synthesis helps translate that goal into practical stabilization layers, including 2′-sugar modifications, phosphorothioate backbone protection, terminal caps, LNA/BNA/cEt affinity tuning, and alternative scaffolds such as PMO and PNA.

2′
SUGAR MODS
OMe • F • MOE • LNA/BNA
PS
BACKBONE
PS • PS₂ • PB • PN/PM
Cap
PROTECTION
End caps • inverted bases • spacers
QC
QC
HPLC/UPLC • LC-MS • CoA
Nuclease Attack vs Protected Oligo Design

A fast visual way to show why stabilization matters: unmodified strands are vulnerable to exonuclease and endonuclease cleavage, while protected designs use layered chemistry to preserve activity.

×
Unmodified Oligo Rapid nuclease degradation
✂
✂
✂
Exonuclease Attack Internal Cleavage Shorter Half-Life
Protection Strategy
  • 2′ Mods
  • PS Backbone
  • Terminal Caps
→
✓
Protected Oligo Enhanced stability & activity
✂
✂
✂
2′ Mods PS Backbone LNA/BNA Terminal Caps
⌛
Increased Serum Half-Life
◎
Improved Target Engagement
🛡
Enhanced Specificity
↗
Better Efficacy Lower Dose
✓
Reduced Off-target Effects
Decision Guide

Choose by What You Need the Oligo to Do

This section turns common customer questions into starting recommendations. Use it like an interactive menu before reviewing the chemistry tables.

ASO

I need a stable antisense oligo

Start with a phosphorothioate backbone and 2′-OMe, 2′-MOE, LNA, BNA or cEt wing design. Decide whether RNase H activity is required.

Gap

I need RNase H cleavage

Use a gapmer concept: modified wings for stability and affinity, with a central DNA gap to support RNase H recruitment.

siRNA

I need a stabilized siRNA

Use 2′-OMe and 2′-F placement to stabilize guide/passenger strands while preserving RISC activity and seed-region behavior.

Apt

I need a stable aptamer

Protect ends with inverted bases or caps; add 2′-OMe, 2′-F, LNA or PEG only where folding and target binding are preserved.

SSO

I need splice modulation

Consider 2′-MOE/PS, PMO, PNA or steric-blocking ASO designs. RNase H activity is usually not desired for splice switching.

Probe

I need a diagnostic probe

Use LNA/BNA/cEt or 2′-OMe to increase Tm and stability while preserving mismatch discrimination and assay compatibility.

Ser

I need serum stability

Combine end protection, PS linkages and selected 2′ modifications. Avoid over-modification if binding kinetics or enzyme compatibility matter.

Max

I need maximum resistance

Use PMO or PNA when enzyme-proof neutrality is preferred. Plan delivery, solubility and conjugation early.

Chemistry Toolkit

Nuclease Resistance Chemistry Toolkit: What Bio-Synthesis Offers

Sugar modifications, base analogs and backbone modifications are all important, but they should be easier to scan. This tabbed toolkit keeps the full offer listed while reducing page length.

↓ Click a tab below to explore available modification chemistries and design options

Sugar modifications that improve nuclease resistance and hybridization stability.

Modification Structure / Class Mechanism & Notes Stability Impact Typical Use
2′-O-Methyl (2′-OMe) 2′-O substitution Reduces RNase access; maintains A-form geometry and improves duplex stability. Moderate nuclease resistance; increased Tm. ASO wings, probes, siRNA, aptamers
2′-Fluoro (2′-F) 2′-F substitution Electronegative fluorine biases C3′-endo sugar pucker; tightens duplex and reduces RNase susceptibility. High resistance; increased Tm. siRNA, ASO, aptamers
2′-MOE 2′-O-methoxyethyl Bulky ethoxy group blocks nucleases; widely used in ASO gapmer wing designs. Strong resistance; increased Tm. ASO gapmer wings, steric-blocking ASO
LNA / BNA / cEt Bridged / constrained sugar Preorganizes sugar geometry for very strong binding and exonuclease resistance. Very high resistance; large Tm increase. ASO, probes, short high-affinity oligos
ENA / AmNA bridge Alternative bridged sugars Balance affinity, toxicity and stability for newer antisense designs. High resistance; increased Tm. ASO and RNA-targeting designs
UNA Unlocked acyclic sugar Increases flexibility; can reduce Tm and tune local structure. Context-dependent resistance; lower binding. Structure tuning, siRNA fine-tuning
GNA / TNA / HNA XNA artificial sugars Artificial sugar frameworks resist biological enzymes and enable specialized duplexing. Excellent resistance; variable Tm. Diagnostics and specialty research

Design note:Sugar modifications are usually the first stabilization layer for ASO wings, siRNA, aptamers and high-stability probes. Use high-affinity residues selectively to avoid off-target binding or loss of useful dynamics.

Base analogs that can assist stabilization or structure tuning.

Modification Structure / Class Mechanism & Notes Impact Typical Use
5-Me-dC / 5-Me-dU Methylated pyrimidines Enhanced hydrophobicity and stacking; modest duplex stabilization. Slight Tm increase; limited direct nuclease effect. Probe tuning, affinity support
Halogenated dU/dC 5-Br, 5-F, 5-I substitutions Improved stacking, minor protection and optional photoreactivity tuning. Small Tm increase; minor resistance. Probe and structure studies
Ψ / s²U Modified RNA bases Improves RNA stability or translation context; can be harder to hydrolyze in some settings. Modest stability; context-dependent. RNA oligos, modified RNA research
N4-Ethyl C Modified cytosine analog Can tune base-pairing and local duplex behavior. Context-dependent Tm and specificity effect. Affinity and specificity tuning
N6-Methyl A Modified adenine analog Useful for RNA motif, stability and structure-function studies. Context-dependent stability effect. RNA structure and motif studies
2-Amino A Adenine analog Can increase hydrogen bonding and duplex strength. Potential affinity increase. Probe and binding studies
7-deaza A / 7-deaza G Deazapurine base analogs Modify hydrogen bonding, stacking and structure behavior. Structure-dependent. Structure probing and difficult sequences
8-oxo G Oxidative lesion analog Useful as lesion mimic or repair study base. Not primarily a stabilizer. Damage / repair studies
Propyne dC / Propyne dU 5-propynyl pyrimidines Increase base stacking and duplex affinity. Tm increase; modest stability support. High-affinity probes

Usage note: Base analogs are best used as fine-tuning elements. For robust nuclease resistance, combine them with sugar or backbone modification strategies.

Backbone modifications for nuclease-resistant oligonucleotide design.

Modification Structure / Class Mechanism & Notes Stability & Use Typical Use
Phosphorothioate (PS) Non-bridging oxygen replaced by sulfur Disrupts nuclease binding; standard backbone strategy for ASO and siRNA stability. Moderate to strong resistance; improves PK. ASO, gapmers, mixmers, terminal siRNA protection
Phosphorodithioate (PS₂) Both non-bridging oxygens replaced by sulfur Higher hydrophobicity and resistance than PS. Very strong resistance. Advanced stabilized designs
Boranophosphate (PB) BH₃ substitution Increases lipophilicity and reduces nuclease affinity while retaining charge. Strong resistance; possible delivery benefits. Advanced ASO / RNA-targeting research
Phosphoramidate (PN) Phosphoramidate linkage Alters charge, nuclease recognition and enzyme compatibility. Excellent resistance; context-dependent duplex effect. Steric-blocking and specialty oligos
Methylphosphonate (PM) Neutral charge-modified backbone Neutralizes backbone and lowers nuclease recognition. Excellent resistance; monitor duplex Tm. Charge-tuning and uptake studies
PMO / Morpholino Morpholine rings with phosphorodiamidate linkage Neutral backbone with no natural nuclease substrate. Extreme resistance. Splice modulation and steric-blocking designs
PNA Peptide-like N-(2-aminoethyl)-glycine backbone No phosphodiester backbone and strong target binding. Extreme resistance; strong binding. Diagnostics, clamps, difficult targets

Backbone note: PS is the common ASO/gapmer backbone. PMO and PNA are best when maximum nuclease resistance and steric-blocking behavior are required.

Selection Guide

Choose by Function, Affinity and Mechanism

For therapeutic-style designs, avoid choosing a chemistry only for stability. The best design depends on whether the oligo needs RNase H cleavage, steric blocking, RISC compatibility, folding preservation or diagnostic specificity.

1. Sugar Layer

Improves stability, affinity and RNA/DNA duplex behavior.

2′-OMe2′-F2′-MOELNA/BNA

2. Backbone Layer

Protects against nucleases and changes charge/protein-binding behavior.

PSPS₂PBPN/PM

3. End Protection

Blocks exonuclease entry and improves serum persistence.

3′ inverted dTcapsspacers

4. Scaffold Swap

Use when maximum nuclease resistance or steric blocking is needed.

PMOPNAXNA

Function-Based Stabilizer Selection

Compact comparison aligned with the page container.

2′-OMe

Balanced RNA Stability

Improves RNA stability and reduces nuclease digestion with a moderate Tm increase.

Best fit:
siRNA, aptamers, steric-blocking ASO, probes

2′-F

Strong RNA Duplex Support

Supports high affinity for RNA targets and strong nuclease resistance.

Best fit:
siRNA, aptamers, RNA-targeting oligos

2′-MOE

ASO Wing Stabilization

High nuclease resistance and improved ASO tolerability profile.

Best fit:
ASO wings, steric-blocking ASO, therapeutic research

LNA / BNA / cEt

High-Affinity Designs

Constrained sugar geometry provides high to very high Tm increase.

Best fit:
Gapmers, SNP probes, short high-affinity oligos

Phosphorothioate

Backbone Protection

Provides backbone nuclease resistance and protein-binding support.

Best fit:
ASO, gapmer, splice modulation, serum stability

PS₂ / PB / PN / PM

Advanced Backbone Tuning

Specialized backbone stabilization for charge, uptake and PK tuning.

Best fit:
Advanced ASO, aptamer and uptake/PK studies

3′ Caps / Inverted Bases

Terminal Protection

Blocks exonuclease attack at termini with minimal effect outside the binding core.

Best fit:
Aptamers, probes, capture oligos

PMO / PNA

Maximum Scaffold Resistance

Very high enzyme resistance from neutral, non-natural scaffolds.

Best fit:
Splice modulation, steric blocking, clamps
Quick Recipe Tables

Practical Starting Points by Modality

These are not final universal designs. They are practical starting points to discuss with Bio-Synthesis when you know the application but need modification guidance.

ASO / Gapmer Quick Recipe

Useful when the design must combine nuclease resistance, target affinity and RNase H-compatible cleavage.

Common stabilized ASO and gapmer design starting points.

Goal Typical Pattern Modification Strategy Key Caution
RNase H gapmer Modified wings + central DNA gap PS backbone with 2′-MOE, LNA/BNA or cEt wings Do not over-modify the DNA gap
Steric-blocking ASO Fully modified or non-cleaving design 2′-OMe, 2′-MOE, PMO or PNA RNase H cleavage is not desired
Splice-switching oligo Stable steric blocker 2′-MOE/PS, PMO, PNA or related scaffold Delivery and exon-target accessibility matter
High-affinity short ASO Selective LNA/BNA/cEt placement Add constrained residues to raise Tm Too much affinity can increase off-target binding

siRNA Quick Recipe

Useful when the design must survive nucleases while preserving guide loading and gene-silencing activity.

Common stabilized siRNA modification starting points.

Goal Typical Pattern Modification Strategy Key Caution
General siRNA stability Selective 2′-OMe / 2′-F placement Modify non-critical positions on guide/passenger strands Avoid disrupting Ago2 loading or seed behavior
Reduce immune stimulation 2′-OMe at selected immune-sensitive motifs Balance potency with reduced innate immune activation Validate activity in final cell model
Increase serum persistence Terminal PS and selected 2′ modifications Add light terminal backbone protection Too much PS can alter protein binding
Conjugated siRNA Stabilized duplex plus ligand Combine 2′ mods with GalNAc, lipid or peptide conjugation Linker and placement must preserve activity
Special Formats

Aptamer, PMO and PNA Stabilization Guidance

Aptamers, PMO and PNA designs require different thinking because stability, folding, binding and delivery can compete with each other.

Apt

Aptamer Stabilization

Use 3′ inverted dT, terminal capping, 2′-OMe, 2′-F, LNA mixmers or PEG/conjugates only where folding and target affinity are preserved.

  • Validate KD in final buffer
  • Protect ends first
  • Avoid altering binding loops
PMO

PMO / Morpholino Designs

PMO designs are highly nuclease-resistant and often used for splice modulation or steric blocking. Delivery conjugation is often important.

  • Neutral scaffold
  • No RNase H activity
  • Useful for splice switching
PNA

PNA Designs

PNA provides strong binding and high nuclease resistance, but may require solubility, delivery and spacing adjustments.

  • Very strong binding
  • Neutral peptide-like backbone
  • Good for clamps and difficult targets
Applications

Where Stabilized Oligonucleotides Are Used

Stability modifications are selected differently depending on whether the oligo needs cleavage, blocking, RISC activity, capture, folding or diagnostic specificity.

ASO

Antisense Oligos

Stabilized ASO and gapmer designs using PS, 2′-MOE, LNA/BNA, cEt and related chemistries.

Explore →

Gap

Gapmer ASO

RNase H-compatible gapmers with stabilized wings and central DNA gap design.

Explore →

RNAi

siRNA & RNAi

2′-OMe, 2′-F and terminal backbone tuning for siRNA stability and activity.

Explore →

Apt

Aptamers

End protection and selective 2′ modifications for serum stability while preserving folding.

Explore →

SSO

Splice-Switching Oligos

Steric-blocking ASO, PMO and PNA-style strategies for splice modulation research.

Explore →

PMO

PMO / Morpholino

Highly nuclease-resistant neutral oligonucleotide scaffolds for blocking and splice applications.

Explore →

PNA

PNA Oligos

Strong-binding, nuclease-resistant PNA designs for clamps, probes and difficult targets.

Explore →

Tx

Therapeutic Research

Phase-appropriate stabilized oligo synthesis, purification, QC and documentation support.

Explore →

Frequently Asked Questions

FAQ

Is nuclease resistance a modification or a function?
Nuclease resistance is a function or property. It is achieved by applying modification types such as 2′-modified sugars, phosphorothioate backbones, terminal caps, PMO or PNA scaffolds.
When should I choose PMO or PNA?
Choose PMO or PNA when maximum nuclease resistance and neutral scaffold behavior are required. PMO is widely used for splice modulation, while PNA provides very strong binding.
What is the fastest way to stabilize an ASO?
Start with a phosphorothioate backbone plus 2′-OMe, 2′-MOE, LNA/BNA or cEt wings. For RNase H activity, preserve a central DNA gap.
What is a thiomorpholino oligonucleotide?
Thiomorpholino is a morpholino-class backbone variant incorporating thio features. Like PMO, it is neutral and highly nuclease-resistant and is explored for splice modulation and delivery conjugation strategies.
What is BNA and how does it compare to LNA?
BNA refers to bridged nucleic acid chemistries, including LNA-like constrained sugars such as cEt, ENA and AmNA families. They increase affinity and nuclease resistance with tunable design behavior.
Do you offer stereodefined PS backbones?
Stereo-enriched or defined phosphorothioate strategies can be discussed on request, balancing potency, off-target protein binding and manufacturability.
Can Bio-Synthesis produce multi-gram stabilized oligonucleotides?
Yes. Bio-Synthesis supports bench to multi-gram stabilized oligonucleotide production with phase-appropriate purification, analytical QC, CoA and documentation support.
Which is better for extreme stability: PMO or PNA?
Both are highly enzyme-resistant. PMO is commonly used for splice-modulating ASOs, while PNA shows very strong binding and often benefits from delivery or solubility design support.
More FAQ'sAll FAQ's
Before Requesting a Quote

Information Helpful for Stabilized Oligo Design

Application
ASO, siRNA, aptamer, PMO, PNA
Mechanism
Cleavage, blocking, folding, RISC
Target
DNA, RNA, splice site, protein
Exposure
Serum, lysate, cells, in vivo
Chemistry
2′ mods, PS, caps, PMO/PNA
QC
HPLC/UPLC, LC-MS, CoA
Contact & Quote Request

Need help selecting a nuclease-resistance strategy?

Share your application, sequence, target type, desired mechanism, exposure environment, modification preference, scale, purification level and QC needs. Bio-Synthesis can help translate the application into a practical stabilized oligonucleotide design.
Request a Quote Speak to a Scientist

Need help before quoting?

Email: info@biosyn.com
Phone: 800-227-0627 (US/CAN)
Phone: +001-972-420-8505 (INT)
2′

Related Services

Related therapeutic, RNAi, PMO, PNA and affinity-enhanced oligo services.

ASO RNAi / siRNA PMO PNA High-Affinity Oligos
✓

Fast Quote Checklist

Include application, sequence, mechanism, exposure condition, chemistry and QC.

Application Sequence Mechanism Chemistry QC
Scientific Background & Recommended Reading

Recommended Reading & Literature References

Selected references covering nuclease-resistant oligonucleotide design, sugar-modified oligos, antisense mechanisms, LNA/BNA, cEt, PMO, PNA and approved therapeutic oligonucleotide chemistry.

  1. Deleavey GF, Damha MJ. Designing chemically modified oligonucleotides for targeted gene silencing. Chemistry & Biology. 2012;19(8):937–954.
  2. Bennett CF, Swayze EE. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annual Review of Pharmacology and Toxicology. 2010;50:259–293.
  3. Prakash TP. An overview of sugar-modified oligonucleotides for antisense therapeutics. Chemistry & Biodiversity. 2011;8(9):1616–1641.
  4. Obika S, Uneda T, Sugimoto T, et al. 2′-O,4′-C-methylene bridged nucleic acid (2′,4′-BNA): synthesis and triplex-forming properties. Bioorganic & Medicinal Chemistry. 2001;9(4):1001–1011.
  5. Seth PP, et al. cEt bridged nucleic acids in antisense designs. Journal of Medicinal Chemistry. 2010.
  6. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Development. 1997;7(3):187–195.
  7. Nielsen PE, Egholm M, Berg RH, Buchardt O. Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science. 1991;254(5037):1497–1500.
  8. Egli M, Manoharan M. Chemistry, structure and function of approved oligonucleotide therapeutics. Nucleic Acids Research. 2023;51(6):2529–2573.

Note: Literature references provide scientific background and should be evaluated within the final application, target biology, chemistry placement, purification and validation workflow.

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links